15,245 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,245 shares of the company's stock, valued at approximately $853,000.

Other hedge funds also recently made changes to their positions in the company. SRS Capital Advisors Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. purchased a new position in Rhythm Pharmaceuticals during the 4th quarter valued at about $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth $37,000. R Squared Ltd purchased a new stake in Rhythm Pharmaceuticals during the fourth quarter valued at approximately $44,000. Finally, Swiss National Bank grew its stake in shares of Rhythm Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 90,200 shares of the company's stock worth $5,049,000 after acquiring an additional 900 shares during the last quarter.

Insider Transactions at Rhythm Pharmaceuticals

In related news, CAO Christopher Paul German sold 635 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the sale, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at approximately $2,078,247.60. This represents a 65.01% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,544 shares of company stock worth $8,245,925 over the last quarter. 5.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

RYTM has been the subject of several recent research reports. Stifel Nicolaus started coverage on shares of Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price for the company. Bank of America raised shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price target for the company in a research note on Monday, April 7th. Wells Fargo & Company boosted their target price on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a research report on Monday, April 7th. Canaccord Genuity Group upped their price target on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price objective (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $75.38.

Rhythm Pharmaceuticals Price Performance

NASDAQ:RYTM traded up $0.91 on Monday, reaching $58.29. The stock had a trading volume of 61,166 shares, compared to its average volume of 546,295. Rhythm Pharmaceuticals, Inc. has a 12-month low of $35.17 and a 12-month high of $68.58. The company has a market cap of $3.71 billion, a price-to-earnings ratio of -13.63 and a beta of 2.36. The firm's fifty day moving average is $56.95 and its two-hundred day moving average is $57.10.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The firm had revenue of $37.72 million for the quarter, compared to analysts' expectations of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business's quarterly revenue was up 25.9% on a year-over-year basis. During the same period in the previous year, the company posted ($2.35) EPS. As a group, research analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.